Funding for this research was provided by:
fundação oswaldo cruz
Received: 21 June 2021
Accepted: 21 December 2021
First Online: 8 January 2022
: The clinical study protocol and informed consent were reviewed and approved by the Ethics Committee at the University of Jaguariuna (CAAE 67860317.3.0000.5409, CAAE 33704720.5.0000.5599, CAAE 09981119.5.0000.5599). Informed consent from all participants was acquired before the study initiation, as declared in the ethics and regulatory statement. All signed informed consent forms are kept for at least five years after the study end.
: The confidentiality of the patients’ records has been observed according to ethical regulations.
: The authors declare following competing interests and financial disclosure: Alessandra Lanzillotta Esteves, Juliana J. Soares Medeiros, Jorge Souza Mendonça are employees of the Institute of Drug Technology (Farmanguinhos), Oswaldo Cruz Foundation (Fiocruz), a Brazilian governmental institution of Ministry of Health. Farmanguinhos is the study sponsors. They were involved in the decision to publish and preparation of the manuscript. Farmanguinhos does not sell medicine on the market. The Brazilian Ministry of Health exclusively drives its drug production. These disclosures do not alter our adherence policies on sharing data and materials. There are no restrictions on the sharing of data and/or materials.